NCT03001869View on ClinicalTrials.gov

68Ga-PSMA PET/CT in Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-HBED-CC-PSMA PET/CT

68Ga-HBED-CC-PSMA PET/CT Scan

Trial Locations (1)

H3T1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

NCT03001869 - 68Ga-PSMA PET/CT in Prostate Cancer | Biotech Hunter | Biotech Hunter